Clinical Trial Update: Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety, tolerability, pharmacokinetics, and exploratory efficacy of AIR DNase in cystic fibrosis patients previously tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• AIR DNAse (deoxyribonuclease)
• Pulmozyme (dornase alfa)

Snippet

Sponsor: Protalix | Conditions: Cystic Fibrosis | Phase 2 | Status: UNKNOWN